ReviewNature cell biology2020
RNA-targeting CRISPR systems from metagenomic discovery to transcriptomic engineering.
Review in Nature cell biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Lentiviral RNAi for Depletion of Enhancer RNAs in Primary Neurons.Methods in molecular biology (Clifton, N.J.) · 2027Article
- CRISPR-mediated engineering of mesenchymal stromal/stem cells: a summary of recent progress in immunological applications for regenerative medicine and cancer therapy.Stem cell research & therapy · 2025Review
- Overcoming the Delivery Challenges in CRISPR/Cas9 Gene Editing for Effective Cancer Treatment: A Review of Delivery Systems.International journal of medical sciences · 2025Review
- Strategies for programmable manipulation of alternative splicing.Current opinion in genetics & development · 2024Review
- Structures, mechanisms and applications of RNA-centric CRISPR-Cas13.Nature chemical biology · 2024Review
- Emerging technology has a brilliant future: the CRISPR-Cas system for senescence, inflammation, and cartilage repair in osteoarthritis.Cellular & molecular biology letters · 2024Review
- Prediction of on-target and off-target activity of CRISPR-Cas13d guide RNAs using deep learning.Nature biotechnology · 2024Article
- Develop a Compact RNA Base Editor by Fusing ADAR with Engineered EcCas6e.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing.Nature communications · 2023Review
- Site-directed RNA editing by harnessing ADARs: advances and challenges.Functional & integrative genomics · 2022Review
- Structural insights into target DNA recognition and cleavage by the CRISPR-Cas12c1 system.Nucleic acids research · 2022Article
- Transcriptomics and RNA-Based Therapeutics as Potential Approaches to Manage SARS-CoV-2 Infection.International journal of molecular sciences · 2022Review
- Type III-A CRISPR systems as a versatile gene knockdown technology.RNA (New York, N.Y.) · 2022Article
- Specific knockdown ofMolecular therapy. Nucleic acids · 2022Article
- Functional genomics and the future of iPSCs in disease modeling.Stem cell reports · 2022Review
- Engineering Closed-Loop, Autoregulatory Gene Circuits for Osteoarthritis Cell-Based Therapies.Current rheumatology reports · 2022Review
- Crosstalk between CRISPR-Cas9 and the human transcriptome.Nature communications · 2022Article
- Double-edged role of resource competition in gene expression noise and control.Advanced genetics (Hoboken, N.J.) · 2022Article
- Chemically modified guide RNAs enhance CRISPR-Cas13 knockdown in human cells.Cell chemical biology · 2022Article
- Emerging strategies for the genetic dissection of gene functions, cell types, and neural circuits in the mammalian brain.Molecular psychiatry · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Deployment of RNA-guided DNA endonuclease CRISPR-Cas technology has led to radical advances in biology. As the functional diversity of CRISPR-Cas and parallel systems is further explored, RNA manipulation is emerging as a powerful mode of CRISPR-based engineering. In this Perspective, we chart progress in the RNA-targeting CRISPR-Cas (RCas) field and illustrate how continuing evolution in scientific discovery translates into applications for RNA biology and insights into mysteries, obstacles, and alternative technologies that lie ahead.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.